DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zebeta (Bisoprolol Fumarate) - Published Studies

 
 



Zebeta Related Published Studies

Well-designed clinical trials related to Zebeta (Bisoprolol)

Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. [2011.07]

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. [2011.06]

Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II). [2011.02]

Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. [2011.01.15]

The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. [2010.09.24]

Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. [2010.06]

Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. [2009.07]

Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). [2009.06]

Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. [2008.06]

Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure. [2007.12]

Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? [2007.08]

Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. [2007.07]

Bisoprolol in the treatment of chronic heart failure. [2007]

Effect of prophylactic bisoprolol plus magnesium on the incidence of atrial fibrillation after coronary bypass surgery: results of a randomized controlled trial. [2006.08]

Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. [2006]

Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. [2005.10.18]

[The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus] [2005.07]

Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. [2004.06]

Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. [2004.03.15]

Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison. [2004]

[Assessment of the efficacy of bisoprolol administration by cardiopulmonary exercise testing in patients with heart failure] [2003.12]

Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. [2003.11.01]

Increased plasma concentration of natriuretic peptides by selective beta1-blocker bisoprolol. [2003.10]

Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)). [2003.08]

[Factors predicting blood pressure normalization in hypertensive patients treated with a fixed-dose combination of bisoprolol 2.5 mg/hydrochlorothiazide/6.25 mg] [2003.07]

Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). [2003.05]

Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). [2003.03]

[Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol] [2003]

Relationships between the antihypertensive effects of bisoprolol and levels of plasma atrial natriuretic peptide in hypertensive patients. [2002.10]

Efficacy of domestic bisoprolol,enalapril and nifedipine retard in mild to moderate hypertension: a randomized double-blind multicenter clinical trial in China. [2002.07]

Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. [2002.04]

Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly. [2002.02]

Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). [2001.12]

Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. [2001.08]

Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. [2001.08]

Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. [2001.07]

Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man. [2001.06]

Effect of bisoprolol on QT dispersion in patients with congestive heart failure--the etiology-dependent response. [2001.02]

Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). [2001.01.23]

[Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study] [2000.12.15]

Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: an angiographic study in patients with maintained vessel patency. [2000.12]

[Comparative study between bisoprolol and metoprolol, combined with hydrochlorothiazide, as antihypertensive therapy] [2000.11]

Bisoprolol alone and in combination with amlodipine or nifedipine in the treatment of chronic stable angina. [2000.07]

Well-designed clinical trials possibly related to Zebeta (Bisoprolol)

Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. [2011.07.27]

Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. [2011]

Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. [2010.09]

Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover myocardial perfusion imaging study. [2010.07]

Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. [2010.05]

Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. [2010.04.27]

Differential effects of beta-adrenoreceptor antagonists on central and peripheral blood pressure at rest and during exercise. [2010.04]

Impact of prophylactic beta-blocker therapy to prevent stroke after noncardiac surgery. [2010.01.01]

Differential effects of oral beta blockade on cardiovascular and sympathetic regulation. [2009.12]

CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men. [2009.10]

Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF. [2009.08]

Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). [2009.07.15]

Use of a nurse-led intervention to optimize beta-blockade for reducing cardiac events after major noncardiac surgery. [2009.04]

Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients. [2009.04]

Beta-adrenergic blockade and metabo-chemoreflex contributions to exercise capacity. [2008.11]

A Review of Evidence-Based beta-Blockers in Special Populations With Heart Failure. [2008.03]

Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. [2008.01]

Pediatric Heart Failure Therapy with beta-Adrenoceptor Antagonists. [2008]

Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker? [2007.09]

The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. [2007.09]

Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study. [2007.09]

A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot. [2007.08]

Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). [2007.03]

Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. [2007.02]

[Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy] [2007]

Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II. [2007]

The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. [2006.11]

Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study. [2006.08]

Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. [2006.07.11]

Beta1-adrenoceptor mediated origin of the heart rate performance curve deflection. [2005.10]

BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. [2005.09]

Early initiation of beta blockade in heart failure: issues and evidence. [2005.09]

[Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure] [2005.07]

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. [2005.01]

Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. [2005]

Effects of a mononitrate, a beta1-blocker and a dihydropyridine calcium channel blocker on cardiovascular responsiveness to passive orthostasis: a placebo-controlled double-blind study in normotensive volunteers. [2005]

Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. [2004.11]

Treatment of acute coronary syndromes in patients with type 2 diabetes mellitus with beta-adrenoblockers and angiotensin-converting enzyme inhibitors: cardiohemodynamic effects and impact for prognosis. [2004.09]

Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. [2004.07.12]

Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade. [2004.06]

[Cardiovascular response to mental and physical stress in hyper-reactive normotensive subjects. Beta blockade effect] [2004]

Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. [2003.11]

A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. [2003.10]

How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). [2003.09]

Influence of beta-blocker use on percentage of target heart rate exercise prescription. [2003.08]

Beta-blocker benefit according to severity of heart failure. [2003.06]

A comparison of the beta1-selectivity of three beta1-selective beta-blockers. [2003.06]

[Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure] [2003.01.15]

Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. [2002.12]

Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. [2002.11]

Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. [2002.05]

Effect of beta(1)-selective adrenergic blockade on maximal blood lactate steady state in healthy men. [2002.05]

Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). [2002.04.02]

Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. [2002.04]

[The effect of aspirin on rheological properties of erythrocytes in essential hypertension] [2002]

Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. [2001.09]

Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. [2001.09]

[Bisprolol in heart failure: efficacy and costs in a French setting according to CIBIS II] [2001.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017